268 related articles for article (PubMed ID: 33175336)
1. Real-World Data on Nonmedical Use of Tramadol from Patients Evaluated for Substance Abuse Treatment in the NAVIPPRO Addiction Severity Index-Multimedia Version (ASI-MV
Green JL; Dailey-Govoni T; Butler SF
Drug Saf; 2021 Feb; 44(2):235-244. PubMed ID: 33175336
[TBL] [Abstract][Full Text] [Related]
2. Nonmedical Use of Xtampza
Green JL; Robbins RS; Dailey-Govoni T; Butler SF
J Pain Res; 2021; 14():1773-1783. PubMed ID: 34163234
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of nonmedical use and routes of administration for prescription stimulant medications among adults in a substance abuse treatment population.
Burtner J; Behling M; Cassidy T; Butler SF
J Addict Dis; 2018; 37(1-2):34-45. PubMed ID: 30592231
[TBL] [Abstract][Full Text] [Related]
4. Abuse of reformulated OxyContin: Updated findings from a sentinel surveillance sample of individuals assessed for substance use disorder.
Cassidy TA; Thorley E; Black RA; DeVeaugh-Geiss A; Butler SF; Coplan P
J Opioid Manag; 2017; 13(6):425-440. PubMed ID: 29308589
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Abuse and Route of Administration of Extended-Release Tapentadol Among Treatment-Seeking Individuals, as Captured by the Addiction Severity Index-Multimedia Version (ASI-MV).
Vosburg SK; Beaumont J; Dailey-Govoni ST; Butler SF; Green JL
Pain Med; 2020 Sep; 21(9):1891-1901. PubMed ID: 31617931
[TBL] [Abstract][Full Text] [Related]
6. Tramadol non-medical use in Four European countries: A comparative analysis.
Iwanicki JL; Schwarz J; May KP; Black JC; Dart RC
Drug Alcohol Depend; 2020 Dec; 217():108367. PubMed ID: 33153831
[TBL] [Abstract][Full Text] [Related]
7. Nonmedical use of prescription ADHD stimulant medications among adults in a substance abuse treatment population: early findings from the NAVIPPRO surveillance system.
Cassidy TA; McNaughton EC; Varughese S; Russo L; Zulueta M; Butler SF
J Atten Disord; 2015 Apr; 19(4):275-83. PubMed ID: 23900405
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the effectiveness of reformulated extended-release oxycodone with abuse-deterrent properties on reducing non-oral abuse among individuals assessed for substance abuse treatment with the Addiction Severity Index-Multimedia Version (ASI-MV).
Rodriguez RD; Dailey Govoni T; Rajagopal V; Green JL
Curr Med Res Opin; 2023 Apr; 39(4):579-587. PubMed ID: 36762423
[TBL] [Abstract][Full Text] [Related]
9. Abuse risks and routes of administration of different prescription opioid compounds and formulations.
Butler SF; Black RA; Cassidy TA; Dailey TM; Budman SH
Harm Reduct J; 2011 Oct; 8():29. PubMed ID: 22011626
[TBL] [Abstract][Full Text] [Related]
10. National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse.
Butler SF; Budman SH; Licari A; Cassidy TA; Lioy K; Dickinson J; Brownstein JS; Benneyan JC; Green TC; Katz N
Pharmacoepidemiol Drug Saf; 2008 Dec; 17(12):1142-54. PubMed ID: 18932173
[TBL] [Abstract][Full Text] [Related]
11. Tapentadol abuse potential: a postmarketing evaluation using a sample of individuals evaluated for substance abuse treatment.
Butler SF; McNaughton EC; Black RA
Pain Med; 2015 Jan; 16(1):119-30. PubMed ID: 25243972
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Opioids Prescribed for Patients at Risk for Opioid Misuse Before and After Publication of the Centers for Disease Control and Prevention's Opioid Prescribing Guidelines.
Scherrer JF; Tucker J; Salas J; Zhang Z; Grucza R
JAMA Netw Open; 2020 Dec; 3(12):e2027481. PubMed ID: 33263762
[TBL] [Abstract][Full Text] [Related]
13. Understanding abuse of buprenorphine/naloxone film versus tablet products using data from ASI-MV® substance use disorder treatment centers and RADARS® System Poison Centers.
Butler SF; Black RA; Severtson SG; Dart RC; Green JL
J Subst Abuse Treat; 2018 Jan; 84():42-49. PubMed ID: 29195592
[TBL] [Abstract][Full Text] [Related]
14. Misuse of Tramadol in the United States: An Analysis of the National Survey of Drug Use and Health 2002-2017.
Reines SA; Goldmann B; Harnett M; Lu L
Subst Abuse; 2020; 14():1178221820930006. PubMed ID: 32547049
[TBL] [Abstract][Full Text] [Related]
15. Characterization of adolescent prescription drug abuse and misuse using the Researched Abuse Diversion and Addiction-related Surveillance (RADARS(®)) System.
Zosel A; Bartelson BB; Bailey E; Lowenstein S; Dart R
J Am Acad Child Adolesc Psychiatry; 2013 Feb; 52(2):196-204.e2. PubMed ID: 23357446
[TBL] [Abstract][Full Text] [Related]
16. Internet-based survey of nonmedical prescription opioid use in the United States.
Katz N; Fernandez K; Chang A; Benoit C; Butler SF
Clin J Pain; 2008; 24(6):528-35. PubMed ID: 18574362
[TBL] [Abstract][Full Text] [Related]
17. An evaluation of online discussion relating to nonmedical use of prescription opioids within the UK.
Hockenhull J; Black JC; Bletz A; Margolin Z; Olson R; Wood DM; Dart RC; Dargan PI
Br J Clin Pharmacol; 2021 Apr; 87(4):1637-1646. PubMed ID: 33464643
[TBL] [Abstract][Full Text] [Related]
18. Women who abuse prescription opioids: findings from the Addiction Severity Index-Multimedia Version Connect prescription opioid database.
Green TC; Grimes Serrano JM; Licari A; Budman SH; Butler SF
Drug Alcohol Depend; 2009 Jul; 103(1-2):65-73. PubMed ID: 19409735
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of Adults Aged ≥18 Years Evaluated for Substance Use and Treatment Planning - United States, 2019.
Kacha-Ochana A; Jones CM; Green JL; Dunphy C; Govoni TD; Robbins RS; Guy GP
MMWR Morb Mortal Wkly Rep; 2022 Jun; 71(23):749-756. PubMed ID: 35679167
[TBL] [Abstract][Full Text] [Related]
20. Opioid therapy trajectories of patients with chronic non-cancer pain over 1 year of follow-up after initiation of short-acting opioid formulations.
Acharya M; Hayes CJ; Li C; Painter JT; Dayer L; Martin BC
Pain Med; 2024 Mar; 25(3):173-186. PubMed ID: 38243702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
